

plied to a tongue depressor and sucked on (like a lollipop) by the patient for 3–5 min.

In conclusion, heightened awareness of the serious potential complication of methemoglobinemia from the use of topical anesthetics, especially those administered via spray, is particularly important for clinicians involved in endoscopic procedures.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Commentary

Neil S. Harris,* Lindsay A.L. Bazydlo, and William E. Winter

Arterial blood typically transports about 20 mL of oxygen per 100 mL (or approximately 9 mmol O₂/L). Over 98% of the oxygen is bound to hemoglobin. A common misconception is to regard the P_{O₂} as a direct (i.e., linear) indication of blood oxygenation. However, analysis of fresh cell-free plasma yields a perfectly respectable P_{O₂} value, although the hemoglobin concentration of the sample is zero. The starting point for determining the oxygen content of the blood is oxygen saturation of hemoglobin, or SO₂. Oxygen saturation is best determined by multiwavelength spectrophotometry (oximetry) and is defined as the O₂-Hb concentration divided by the sum of the O₂-Hb and deoxy-Hb. An oximeter will also give the O₂-Hb fraction, or F_{O₂Hb}, which is calculated by dividing the O₂-Hb by the sum of all of the hemoglobin fractions (including nonfunctional dyshemoglobins—Met-Hb and CO-Hb—if present). In healthy individuals and in most patients, the oxygen saturation and O₂-Hb fraction are nearly identical. If a substantial proportion of dyshemoglobins are present, the F_{O₂Hb} will be lower than the SO₂ because the latter analyzes only the fully functional hemoglobins and intentionally excludes the nonfunctional dyshemoglobins. For this

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: S.L. Mulvagh, Acusphere Inc. and Point Biomedical Corp.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: None declared.

Expert Testimony: None declared.

Patents: None declared.

Reference

1. Barker SJ, Tremper KK, Hyatt J. Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry. *Anesthesiology* 1989;70:112–7.

reason, the SO₂ is sometimes referred to as the functional saturation.

Most standard pulse oximeters use only 2 wavelengths to determine hemoglobin saturation. Analysis is based upon an assumption that no dyshemoglobins are present. In the presence of either Met-Hb or CO-Hb, the pulse oximetry oxygen saturation will be incorrect—it will match neither the SO₂ nor the fractional saturation determined by multiwavelength oximetry. There is yet another method to determine oxygen saturation. The P_{O₂} and pH can be used to calculate what is sometimes referred to as the O₂sat. Some variations of this calculation include measurements of bicarbonate and hemoglobin. This principle is used by analyzers that do not have oximetry capabilities and by certain point-of-care devices. The O₂sat will be incorrect in the presence of a dyshemoglobin.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: None declared.

Stock Ownership: W.E. Winter, Abbott and Johnson and Johnson.

Honoraria: None declared.

Research Funding: None declared.

Expert Testimony: None declared.

Patents: None declared.

Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville FL.

* Address correspondence to this author at: University of Florida, PO Box 100275, Gainesville, FL 32610-0275. Fax 352-265-0437; e-mail harris@pathology.ufl.edu.

Received September 17, 2013; accepted September 25, 2013.

DOI: 10.1137/clinchem.2013.214270